- Home
- CNSP vs BOLT Comparison
CNSP vs BOLT Comparison
Compare CNSP & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNSP | BOLT |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 7.1M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CNSP | BOLT |
|---|---|---|
| Price | $5.25 | $3.67 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $29.00 |
| AVG Volume (30 Days) | 3.6K | ★ 31.2K |
| Earning Date | 11-16-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.03 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,695,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,525.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 0.07 |
| 52 Week Low | $1.90 | $3.10 |
| 52 Week High | $10.59 | $7.20 |
Technical Indicators
Market Signals| Indicator | CNSP | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 47.24 |
| Support Level | N/A | $3.13 |
| Resistance Level | N/A | $4.34 |
| Average True Range (ATR) | 0.00 | 0.32 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 0.00 | 40.48 |
Price Performance
Historical ComparisonAbout CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.